Alvotech Adds US Manufacturing Capacity with LOTTE Biologics, Partially Mitigating Single-Site Risk

What happened

Alvotech announced a long-term manufacturing partnership with LOTTE Biologics to produce drug substance for multiple biosimilars at LOTTE's Syracuse, New York facility, with potential for expansion over time. This directly addresses a key risk highlighted in our prior analysis: Alvotech's reliance on a single Reykjavik manufacturing site that suffered FDA deficiencies and a complete response letter for AVT05. While the agreement does not immediately resolve those regulatory issues, it offers a path to diversify production and increase global supply capacity. The company remains heavily leveraged with negative equity, and the partnership will likely require additional technology transfer and validation timelines before contributing to revenue. Overall, the news is a positive step but does not alter the near-term financial or regulatory challenges.

Implication

Investors should view the LOTTE Biologics partnership as a long-term risk mitigant rather than a near-term catalyst, as tech transfer and regulatory approval for the new site will take time. The core thesis still hinges on Alvotech remediating Reykjavik deficiencies to secure AVT05 approval and generate positive free cash flow. While additional capacity may lower the probability of a catastrophic supply disruption, it also adds complexity and capital requirements that could strain the balance sheet. We maintain our WAIT rating until we see evidence of regulatory resolution and improved profitability. A sustained move above our trim level of $8.00 would require clear progress on both fronts, while an attractive entry near $3.75 would better price in remaining risks.

Thesis delta

The LOTTE Biologics partnership modestly improves Alvotech's manufacturing resilience by adding a second drug substance site, reducing the single-point-of-failure risk highlighted in our prior report. However, it does not address the unresolved AVT05 CRL or FDA deficiencies at Reykjavik, which remain the primary downside drivers. As such, our WAIT rating stands, but we view the capacity expansion as a step toward de-risking the platform.